Open Targets Genetics will be deprecated on 9 July 2025, after the next release of the Open Targets Platform.
On 9 July, you will no longer be able to access the Open Targets Genetics user interface (genetics.opentargets.org). We will maintain an archive of the data, which will be accessible through the EMBL-EBI FTP.
We've merged the Open Targets Platform and Open Targets Genetics
The March release of the Open Targets Platform (25.03) effectively united the Open Targets Platform and Open Targets Genetics into a one-stop shop for human genetic and target discovery information.
Find out more about our decision to merge the two platforms: A step-change in common disease genetics in the Open Targets Platform
The Platform contains updated and improved Genetics data, with some differences
The Platform now includes comprehensive variant annotation and the results of state-of-the-art large scale statistical analysis, including fine-mapping, colocalisation and locus-to-gene assignment across all complex and molecular traits.
The more than 2.6 million GWAS credible sets identified are contextualised with results from gene burden analysis, pharmacogenetics or predominantly rare variation resources, drawing a richer map of the phenotypic effects of a broader range of variation.
Find out more about the 25.03 release including a walkthrough of the new pages on the blog: Open Targets Platform 25.03 has been released!
We strongly recommend using the updated data and analyses. The 25.03 Platform data release supersedes the last release of Open Targets Genetics with significant updates for statistical genetic analyses and 20% more direct gene-disease associations from GWAS credible sets.
We have improved our genetic analyses with:
quality control and validation of GWAS studies and credible sets
new ancestry-specific fine-mapping
greater coverage of GWAS, diseases and molQTLs
all GWAS vs all GWAS and all GWAS vs all molQTLs colocalisation
a larger training set for our Locus-to-Gene model (L2G), that is less biased towards the nearest gene. L2G model performance results are improved by all measures
feature interpretation of L2G using Shapley values
However, please note that some analyses, such as V2G, are no longer available. We also now only include variants with phenotypic information; so there may be some information you are not able to find.
Where to go for help
We’ve described the changes in the documentation, and included a list of FAQs:
Platform documentation (FAQs): FAQs | Open Targets Platform Documentation
A few issues have already been covered on the Open Targets Community, but please raise additional issues in the relevant categories if you have questions or concerns:
- Breaking changes to Google Big Query following 25.03 update
- Questions about the Open Targets Platform (posterior probability, odds ratio for drug associations, preference for hypothesis-independent genetic data)
- Differences in the coverage of variants: Missing variant in Platform compared to Open Targets Genetics and 25.03 Platform release now live! Open Targets Genetics data update - #2 by alhenry
- OT Platform GWAS credible set issue where there are no L2G predictions > 0.05— being resolved
- Gold standard for new L2G scores
- Best practices for using a pre-trained L2G pipeline on new loci
- V2G deprecation in Upcoming Release (25.03)
